Business
Shareholder update to review AVA6000 Phase 1a data
Shareholder update to review AVA6000 Phase 1a data.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n4 December 2023\n \nAvacta Group plc\n \n(\"Avacta\" or \"the Group\" or \"the Company\")\n \nShareholder update to review AVA6000 Phase 1a data\n \nAvacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will hold an online shareholder event via the Investor Meet Company (\"IMC\") platform on Wednesday 13 December at 11:00 a.m. GMT.\nAvacta's Chief Executive Officer, Alastair Smith, Chief Scientific Officer, Fiona McLaughlin and Consultant Chris Coughlin will present a detailed review of the AVA6000 clinical trial's Phase 1a data, followed by an investor Q&A. Questions can be submitted in advance via the IMC platform.\nInvestors who already follow Avacta on IMC will automatically be invited to join the live stream. Investors who do not have an IMC account can sign up for free at https://www.investormeetcompany.com/avacta-group-plc/register-investor and then click \"Add to meet\" on the Avacta page in order to receive an invitation.\n \n \n-Ends-\n \n \nFor further information from Avacta Group plc, please contact:\n \n\n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\nMichael Vinegrad, Group Communications Director\n\n \n\n\nTel: +44 (0) 1904 21 7070\nwww.avacta.com\n\n\n\n\nStifel Nicolaus Europe Limited (Nomad and Broker)\nNicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / William Palmer-Brown\n \n \n\n\nTel: +44 (0) 207 710 7600\nwww.stifel.com\n\n\n\n\nConsilium Strategic Communications (Media and IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji\n \n\n\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n \nAbout Avacta Group plc - https://www.avacta.com\nAvacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.\n \nAvacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer® immunotherapies and pre|CISION™ tumour targeted chemotherapies. This...